WO2004028456A3 - Method and composition for treating neurodegenerative disorders - Google Patents

Method and composition for treating neurodegenerative disorders Download PDF

Info

Publication number
WO2004028456A3
WO2004028456A3 PCT/US2003/030284 US0330284W WO2004028456A3 WO 2004028456 A3 WO2004028456 A3 WO 2004028456A3 US 0330284 W US0330284 W US 0330284W WO 2004028456 A3 WO2004028456 A3 WO 2004028456A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative disorders
composition
treating neurodegenerative
treating
methods
Prior art date
Application number
PCT/US2003/030284
Other languages
French (fr)
Other versions
WO2004028456A2 (en
Inventor
Adrian Hobden
Jean-Marc Roch
Original Assignee
Myriad Genetics Inc
Adrian Hobden
Jean-Marc Roch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc, Adrian Hobden, Jean-Marc Roch filed Critical Myriad Genetics Inc
Priority to AU2003278935A priority Critical patent/AU2003278935A1/en
Publication of WO2004028456A2 publication Critical patent/WO2004028456A2/en
Publication of WO2004028456A3 publication Critical patent/WO2004028456A3/en
Priority to US11/092,118 priority patent/US20050171207A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds

Abstract

The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an R-NSAID and an HMG-CoA reductase inhibitor. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, mild cognitive impairment
PCT/US2003/030284 2002-09-26 2003-09-26 Method and composition for treating neurodegenerative disorders WO2004028456A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003278935A AU2003278935A1 (en) 2002-09-26 2003-09-26 Method and composition for treating neurodegenerative disorders
US11/092,118 US20050171207A1 (en) 2003-09-26 2005-03-28 Method and composition for combination treatment of neurodegenerative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41404502P 2002-09-26 2002-09-26
US60/414,045 2002-09-26

Publications (2)

Publication Number Publication Date
WO2004028456A2 WO2004028456A2 (en) 2004-04-08
WO2004028456A3 true WO2004028456A3 (en) 2004-06-17

Family

ID=32043333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/030284 WO2004028456A2 (en) 2002-09-26 2003-09-26 Method and composition for treating neurodegenerative disorders

Country Status (2)

Country Link
AU (1) AU2003278935A1 (en)
WO (1) WO2004028456A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2501A (en) 2003-05-30 2012-10-22 Ranbaxy Lab Ltd Substituted pyrrole derivatives
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
EP1948599A1 (en) * 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CN104368002B (en) * 2014-10-17 2019-01-08 中国人民解放军军事医学科学院毒物药物研究所 For treating the combination medicine of dull-witted or cognition dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

Also Published As

Publication number Publication date
AU2003278935A8 (en) 2004-04-19
AU2003278935A1 (en) 2004-04-19
WO2004028456A2 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
SI1509232T1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
WO2004103960A3 (en) Compounds and uses thereof
EP1471909A4 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2004048551A3 (en) Target for therapy of cognitive impairment
EP1201268A3 (en) Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
WO2006055871A3 (en) Treatment for multiple sclerosis
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2003039490A9 (en) Compositions and methods for diagnosing and treating mental disorders
HK1080408B (en) Use of brimonidine in the treatment of dementia and parkinsons disease
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
WO2006020852A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders
RS20050420A (en) Prevention and treatment of alzheimer's disease
WO2006020853A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders
AU2003270446A1 (en) Method and composition for treating alzheimer's disease and dementias of vascular origin
AU2003290970A1 (en) Compositions and method for treating affective, painful or allergic disorders
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP